TGastroenterology. Author manuscript; accessible in PMC 2022 June 01.Mahurkar-Joshi et al.PageAuthor Manuscript Author Manuscript Author Manuscript Author ManuscriptGastroenterology. Author manuscript; out there in PMC 2022 June 01.Figure 1.shows the heatmap from the normalized expression of 12 differentially expressed miRNAs. Heatmap colors range from dark blue, white, and dark red, representing low, typical, and high expression, respectively. Dx, diagnosis; M, Male; F, Female; IBS-C constipationpredominant IBS; IBS-D, diarrhea-predominant IBS. The bottom-panel shows variables linked with the samples.Mahurkar-Joshi et al.PageAuthor Manuscript Author Met medchemexpress ManuscriptFigure 2.shows a network of deregulated genes and select gene ontology (GO) terms associated with all the inhibition of miR-219a-5p. Nodes and edges are described inside the major appropriate panel with the figure.Author Manuscript Author ManuscriptGastroenterology. Author manuscript; readily available in PMC 2022 June 01.Mahurkar-Joshi et al.PageAuthor Manuscript Author Manuscript Author Manuscript Author ManuscriptGastroenterology. Author manuscript; available in PMC 2022 June 01.Figure 3.shows A) western blots of tight junction protein 1 (TJP1 or ZO1) and E-cadherin (CDH1) proteins performed in NCM460 cells, B) Protein levels of ZO1 and CDH1 by densitometry. The error bars AT1 Receptor Antagonist MedChemExpress represent mean standard deviation, as well as the information represent fold adjustments relative to manage. The experiments were performed in duplicate.Mahurkar-Joshi et al.PageAuthor ManuscriptFigure 4.Author Manuscript Author Manuscript Author Manuscriptshows, A) a progressive reduce in trans-epithelial electrical resistance (TEER) more than 3 days in Caco-2 cells treated with miR-219a-5p inhibitor (Anti_miR_219, red line) in comparison to cells treated with control miRNA (Anti_miR_Control, blue line), and B) an enhanced dextran flux over six hours (measured every single 2 hours) in cells treated with miR-219a-5p inhibitor (Anti_miR_219, red line) in comparison to cells treated with manage miRNA (Anti_miR_Control, blue line). , p0.05; , p0.01.Gastroenterology. Author manuscript; accessible in PMC 2022 June 01.Mahurkar-Joshi et al.PageAuthor Manuscript Author ManuscriptFigure five.shows a network of deregulated genes and select gene ontology (GO) terms connected together with the inhibition of hsa-miR-338-3p. Nodes and edges are described within the major correct panel of the Figure.Author Manuscript Author ManuscriptGastroenterology. Author manuscript; obtainable in PMC 2022 June 01.Mahurkar-Joshi et al.PageTable 1:Demographic characteristics of IBS individuals and healthy controlsGroup N Ladies ( ) Age [mean(sd)] BMI [mean(sd)] Ethnicity Hispanic N ( ) Race Asian ( ) Black ( ) White ( ) Other/mixed ( ) Bowel habit subtype IBS-C ( ) IBS-D ( ) HAD anxiousness score (0-21) [mean(sd)] HAD depression score (0-21) [mean(sd)] General IBS severity (0-20) [mean(sd)] Abdominal discomfort (0-20) [mean(sd)] Bloating [mean(sd)] 15 (52) 14 (48) 6.38 (5.9) 3.03 (2.9) ten.4 (4.three) ten.4 (4.two) 12.five (four.1) NA NA 4.27 (4.53) 2.07 (2.43) 9.43 (4.47) 9.14 (four.4) 12.07 (4.four) NA NA 8.64 (6.57) 4.07 (3.08) 11.29 (4.05) 11.57 (3.88) 13.07 (three.97) NA NA 4.0 (three.1) 1.73 (1.94) NA NA NA eight (28) 4 (13) 12 (41) 5 (18) 3 (20) 4 (27) 7 (47) 1 (7) 5 (36) 0 (0) 5 (36) four (28) 3 (20) 1 (7) 8 (53) 3 (20) 4 (14) three (20) 1 (7) two (13) IBS 29 55 33.9 (12.two) 24.69 (5.0) IBS-C 15 67 32 (13.7) 23.98 (three.47) IBS-D 14 43 35.93 (10.five) 25.45 (6.29) HCs 15 47 34.two (9.2) 25.75 (3.1)Author Manuscript Author Manuscript Author Manuscript Author ManuscriptTable 1.
Calcimimetic agent
Just another WordPress site
